Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33526463.
- Also identified by DOI 10.3949/ccjm.88a.19133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The 2019 guideline from the Anticoagulation Forum provides clear instructions on how to use 2 agents for reversing the effects of direct oral anticoagulants (DOACs): idarucizumab for dabigatran-associated bleeding and andexanet alfa for bleeding associated with rivaroxaban and apixaban. The guideline also discusses off-label use of andexanet alfa for bleeding associated with edoxaban and betrixaban and the use of hemostatic agents such as activated prothrombin complex concentrate and 4-factor prothrombin complex concentrate. Lastly, it offers approaches for building and managing stewardship programs at the health system level.
Medical subject headings
- Anticoagulants
- Blood Coagulation